- Report
- June 2021
- 87 Pages
Global
€21856EUR$22,000USD£18,172GBP
- Drug Pipelines
- February 2019
- 300 Pages
Global
From €21856EUR$22,000USD£18,172GBP
- Report
- January 2019
- 14 Pages
United Kingdom
From €595EUR$599USD£495GBP
- Report
- October 2022
- 200 Pages
Global
From €2384EUR$2,400USD£1,982GBP
- Report
- January 2022
- 220 Pages
Global
From €2384EUR$2,400USD£1,982GBP
- Report
- August 2022
- 119 Pages
Global
From €4471EUR$4,500USD£3,717GBP
- Report
- November 2023
- 190 Pages
Global
From €4471EUR$4,500USD£3,717GBP
- Report
- January 2024
- 200 Pages
Japan
From €3999EUR$4,025USD£3,325GBP
€5712EUR$5,750USD£4,750GBP
- Report
- January 2024
- 100 Pages
Japan
From €1321EUR$1,330USD£1,099GBP
€1888EUR$1,900USD£1,569GBP
- Report
- August 2023
- 255 Pages
Global
From €6606EUR$6,650USD£5,493GBP
€9438EUR$9,500USD£7,847GBP
- Report
- August 2023
- 127 Pages
Global
From €3303EUR$3,325USD£2,747GBP
€4719EUR$4,750USD£3,924GBP
- Report
- September 2024
- 82 Pages
Japan
From €3477EUR$3,500USD£2,891GBP
- Report
- December 2022
- 112 Pages
Global
From €4471EUR$4,500USD£3,717GBP
- Report
- November 2023
- 168 Pages
Global
From €2484EUR$2,500USD£2,065GBP
- Report
- April 2023
- 147 Pages
Global
From €5960EUR$5,999USD£4,955GBP
- Drug Pipelines
- May 2023
- 151 Pages
Global
From €10923EUR$10,995USD£9,082GBP
- Report
- March 2023
- 1355 Pages
Global
From €2484EUR$2,500USD£2,065GBP
- Report
- November 2022
- 330 Pages
Global
From €3974EUR$4,000USD£3,304GBP
- Report
- May 2020
- 218 Pages
Global
From €10923EUR$10,995USD£9,082GBP
- Report
- May 2020
- 47 Pages
Global
From €3969EUR$3,995USD£3,300GBP
The Alzheimer's Disease Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs to treat Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia, and is estimated to affect over 5 million people in the United States alone.
The Alzheimer's Disease Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include Eli Lilly, Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are developing and marketing drugs to treat Alzheimer's Disease, such as cholinesterase inhibitors, memantine, and monoclonal antibodies. Additionally, many of these companies are researching and developing new treatments for Alzheimer's Disease, such as gene therapy and stem cell therapy. Show Less Read more